Measures · D06 in 2019 · Part D · DD2 Member Complaints and Changes in the Drug Plan’s Performance
Drug Plan Quality Improvement
Drug PlanQuality ImprovementSource: Star Ratings (improvement)
- What it measures
- This shows how much the drug plan’s performance has improved or declined from one year to the next year. If a plan receives 1 or 2 stars, it means, on average, the plan’s scores declined (got worse). If a plan receives 3 stars, it means, on average, the plan’s scores stayed about the same. If a plan receives 4 or 5 stars, it means, on average, the plan’s scores improved. Keep in mind that a plan that is already doing well in most areas may not show much improvement. It is also possible that a plan can start with low ratings, show a lot of improvement, and still not be performing very well.
- How it's calculated
- The numerator is the net improvement, which is a sum of the number of significantly improved measures minus the number of significantly declined measures. The denominator is the number of measures eligible for the improvement measure (i.e., the measures that were included in the 2017 and 2018 Star Ratings for this contract and had no specification changes).
- Data source
- Star Ratings 2018 and 2019 Star Ratings
- Measurement period
- Not Applicable
- Better when
- Higher
- Weight
- 5 (Improvement Measure)
- Star assignment
- Clustering
- Case-mix adjusted
- —
- In improvement measure
- No
- Used in CAI
- No
- Exclusions
Show
Contracts must have data in at least half of the measures used to calculate improvement to be rated in this measure.- Notes
- Attachment I contains the formulas used to calculate the improvement measure and lists indicating which measures were used.
- Disaster policy
- Includes only measures which have data from both years
From the 2019 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.
How the 2028 cut points are projected
Each boundary moves by its median year-on-year change since 2019, capped at 5 points, the most CMS lets a non-survey cut point move in a year. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.
| Stars | Org type | 2027 | Projected 2028 | Move |
|---|---|---|---|---|
| 2★ | MA-PD | −0.3 | −0.31 | −0.01 |
| 3★ | MA-PD | 0 | 0 | 0 |
| 4★ | MA-PD | 0.23 | 0.27 | +0.04 |
| 5★ | MA-PD | 0.51 | 0.56 | +0.04 |
| 2★ | PDP | −0.14 | −0.08 | +0.07 |
| 3★ | PDP | 0 | 0 | 0 |
| 4★ | PDP | 0.25 | 0.16 | −0.09 |
| 5★ | PDP | 0.5 | 0.54 | +0.04 |
2019 star distribution
Not rated: Plan too new to be measured (133); Not enough data available (115); Plan not required to report measure (11)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2027 | MA-PD | < -0.296792 | >= -0.296792 to < 0 | >= 0 to < 0.231209 | >= 0.231209 to < 0.513866 | >= 0.513866 |
| 2027 | PDP | < -0.142857 | >= -0.142857 to < 0 | >= 0 to < 0.245851 | >= 0.245851 to < 0.502381 | >= 0.502381 |
| 2026 | MA-PD | < -0.233766 | >= -0.233766 to < 0 | >= 0 to < 0.320439 | >= 0.320439 to < 0.579545 | >= 0.579545 |
| 2026 | PDP | < -0.183824 | >= -0.183824 to < 0 | >= 0 to < 0.330927 | >= 0.330927 to < 0.672727 | >= 0.672727 |
| 2025 | MA-PD | < -0.218869 | >= -0.218869 to < 0 | >= 0 to < 0.242468 | >= 0.242468 to < 0.496603 | >= 0.496603 |
| 2025 | PDP | < -0.2825 | >= -0.2825 to < 0 | >= 0 to < 0.273334 | >= 0.273334 to < 0.576667 | >= 0.576667 |
| 2024 | MA-PD | < -0.253472 | >= -0.253472 to < 0 | >= 0 to < 0.206957 | >= 0.206957 to < 0.456458 | >= 0.456458 |
| 2024 | PDP | < -0.123026 | >= -0.123026 to < 0 | >= 0 to < 0.175272 | >= 0.175272 to < 0.38356 | >= 0.38356 |
| 2023 | MA-PD | < -0.325131 | >= -0.325131 to < 0 | >= 0 to < 0.159307 | >= 0.159307 to < 0.391045 | >= 0.391045 |
| 2023 | PDP | < -0.237362 | >= -0.237362 to < 0 | >= 0 to < 0.389234 | >= 0.389234 to < 0.851667 | >= 0.851667 |
| 2022 | MA-PD | < -0.2 | >= -0.2 to < 0 | >= 0 to < 0.428571 | >= 0.428571 to < 0.68421 | >= 0.684211 |
| 2022 | PDP | NA | NA | >= 0 to < 0.545455 | >= 0.545455 to < 0.80952 | >= 0.809524 |
| 2021 | MA-PD | < -0.32 | >= -0.32 to < 0 | >= 0 to < 0.391304 | >= 0.391304 to < 0.592593 | >= 0.592593 |
| 2021 | PDP | < -0.12 | >= -0.12 to < 0 | >= 0 to < 0.086957 | >= 0.086957 to < 0.407407 | >= 0.407407 |
| 2020 | MA-PD | < -0.100 | ? -0.100 to < 0.000 | ? 0.000 to < 0.346 | ? 0.346 to < 0.550 | ? 0.550 |
| 2020 | PDP | < -0.186 | ? -0.186 to < 0.000 | ? 0.000 to < 0.323 | ? 0.323 to < 0.698 | ? 0.698 |
| 2019 | MA-PD | < -0.342 | ? -0.342 to < 0.000 | ? 0.000 to < 0.316 | ? 0.316 to < 0.463 | ? 0.463 |
| 2019 | PDP | NA | NA | ? 0.000 to < 0.341 | ? 0.341 to < 0.512 | ? 0.512 |
| 2018 | MA-PD | < -0.184 | ? -0.184 to < 0.000 | ? 0.000 to < 0.438 | ? 0.438 to < 0.605 | ? 0.605 |
| 2018 | PDP | < -0.125 | ? -0.125 to < 0.083 | ? 0.083 to < 0.438 | ? 0.438 to < 0.600 | ? 0.600 |
| 2017 | MA-PD | < -0.241 | ? -0.241 to < 0.000 | ? 0.000 to < 0.415 | ? 0.415 to < 0.659 | ? 0.659 |
| 2017 | PDP | < -0.149 | ? -0.149 to < 0.000 | ? 0.000 to < 0.415 | ? 0.415 to < 0.657 | ? 0.657 |
| 2016 | MA-PD | < -0.250 | ? -0.250 to < 0.000 | ? 0.000 to < 0.333 | ? 0.333 to < 0.545 | ? 0.545 |
| 2016 | PDP | < -0.273 | ? -0.273 to < 0.000 | ? 0.000 to < 0.333 | ? 0.333 to < 0.545 | ? 0.545 |
| 2015 | MA-PD | < -0.231 | ? -0.231 to < 0.000 | ? 0.000 to < 0.357 | ? 0.357 to < 0.500 | ? 0.500 |
| 2015 | PDP | < -0.154 | ? -0.154 to < 0.000 | ? 0.000 to < 0.357 | ? 0.357 to < 0.500 | ? 0.500 |
Lowest-scoring contracts, 2019
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2027 | D04 | Drug Plan Quality Improvement | Not Applicable | 5 | Star Ratings (improvement) |
| 2026 | D04 | Drug Plan Quality Improvement | Not Applicable | 5 | Star Ratings (improvement) |
| 2025 | D04 | Drug Plan Quality Improvement | Not Applicable | 5 | Star Ratings (improvement) |
| 2024 | D04 | Drug Plan Quality Improvement | Not Applicable | 5 | Star Ratings (improvement) |
| 2023 | D04 | Drug Plan Quality Improvement | Not Applicable | 5 | Star Ratings (improvement) |
| 2022 | D04 | Drug Plan Quality Improvement | Not Applicable | 5 | Star Ratings (improvement) |
| 2021 | D06 | Drug Plan Quality Improvement | Not Applicable | 5 | Star Ratings (improvement) |
| 2020 | D06 | Drug Plan Quality Improvement | Not Applicable | 5 | Star Ratings (improvement) |
| 2019 | D06 | Drug Plan Quality Improvement | Not Applicable | 5 | Star Ratings (improvement) |
| 2018 | D07 | Drug Plan Quality Improvement | Not Applicable | 5 | Star Ratings (improvement) |
| 2017 | D07 | Drug Plan Quality Improvement | Not Applicable | 5 | Star Ratings (improvement) |
| 2016 | D07 | Drug Plan Quality Improvement | Not Applicable | 5 | Star Ratings (improvement) |
| 2015 | D05 | Drug Plan Quality Improvement | Not Applicable | 5 | Star Ratings (improvement) |